Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Karin Kato, Sho Kodama, Kazuhito Shiosakai & Takeshi Kimura. (2023) Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study. Expert Opinion on Pharmacotherapy 24:2, pages 267-282.
Read now
Read now
Articles from other publishers (11)
Mellar Davis & Charles Loprinzi. (2022) Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study. Supportive Care in Cancer 30:11, pages 8845-8853.
Crossref
Crossref
Timothy M. Rankin, John D. Miller, Angelika C. Gruessner & D. Scott Nickerson. (2015) Illustration of Cost Saving Implications of Lower Extremity Nerve Decompression to Prevent Recurrence of Diabetic Foot Ulceration. Journal of Diabetes Science and Technology 9:4, pages 873-880.
Crossref
Crossref
Lindsay Parker, Rachel Huelin, Zarmina Khankhel, Radek Wasiak & Joaquin Mould. (2015) A Systematic Review of Pharmacoeconomic Studies for Pregabalin. Pain Practice 15:1, pages 82-94.
Crossref
Crossref
Stephen S. Johnston, Margarita Udall, Joseph C. Cappelleri, Barbara H. Johnson, George Shrady, Bong-Chul Chu & Stuart L. Silverman. (2014) Potential Drug–Drug and Drug–Condition Interactions among Fibromyalgia Patients Initiating Pregabalin or Duloxetine: Prevalence and Health Care Expenditure Impact. Pain Medicine 15:8, pages 1282-1293.
Crossref
Crossref
Stephen S. Johnston, Margarita Udall, Jose Alvir, Donna McMorrow, Robert Fowler & Daniel Mullins. (2014) Characteristics, Treatment, and Health Care Expenditures of Medicare Supplemental-Insured Patients with Painful Diabetic Peripheral Neuropathy, Post-Herpetic Neuralgia, or Fibromyalgia. Pain Medicine 15:4, pages 562-576.
Crossref
Crossref
Stephen S. Johnston, Margarita Udall, Joseph C. Cappelleri, Barbara H. Johnson, George Shrady, Bong-Chul Chu & Stuart L. Silverman. (2013) Cost comparison of drug–drug and drug–condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. American Journal of Health-System Pharmacy 70:24, pages 2207-2217.
Crossref
Crossref
Polina Feldman & Rajesh Khanna. (2013) Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides. Neuroscience Letters 557, pages 27-36.
Crossref
Crossref
Antoni Sicras, Javier Rejas, Ruth Navarro & Albert Planas. (2013) Adding Pregabalin or Gabapentin for the Management of Community-Treated Patients with Painful Diabetic Peripheral Neuropathy: A Comparative Cost Analysis. Clinical Drug Investigation 33:11, pages 825-835.
Crossref
Crossref
Margarita Udall, Jack Mardekian & Javier Cabrera. (2013) Identification of Patients with Painful Diabetic Peripheral Neuropathy Who Have a Favorable Cost Profile with Pregabalin Treatment. Pain Practice 13:6, pages 476-484.
Crossref
Crossref
M Gore, N Brix Finnerup, A Sadosky, K-S Tai, J C Cappelleri, J Mardekian, C George Rice & E Nieshoff. (2012) Pain-related pharmacotherapy, healthcare resource use and costs in spinal cord injury patients prescribed pregabalin. Spinal Cord 51:2, pages 126-133.
Crossref
Crossref
Nathan L. Kleinman, Alesia Sadosky, Jaren Seid, Roy C. Martin & David M. Labiner. (2012) Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin. Epilepsy Research 102:1-2, pages 13-22.
Crossref
Crossref